CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).

Russell K. Pachynski,Margitta Retz,Jeffrey C. Goh,Mauricio Burotto,Gwenaelle Gravis,Daniel Castellano,Aude Flechon,Stefanie Zschaebitz,David R. Shaffer,Juan Carlos Vázquez-Limón,Marc-Oliver Grimm,Steven L. McCune,Neha P. Amin,J. Li,Xuya Wang,Keziban Unsal-Kacmaz,Fred Saad,Daniel P. Petrylak,Karim Fizazi

CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).

2021

Russell K. Pachynski
Margitta Retz
Jeffrey C. Goh
Mauricio Burotto
Gwenaelle Gravis
Daniel Castellano
Aude Flechon
Stefanie Zschaebitz
David R. Shaffer
Juan Carlos Vázquez-Limón
Marc-Oliver Grimm
Steven L. McCune
Neha P. Amin
J. Li
Xuya Wang
Keziban Unsal-Kacmaz
Fred Saad
Daniel P. Petrylak
Karim Fizazi

5044Background: CheckMate 9KD is a phase 2 trial of NIVO (anti-PD-1) combined with either rucaparib, docetaxel, or enzalutamide for mCRPC. PARP inhibitors, like rucaparib, increase cellular DNA dam...

Keywords:

Docetaxel
Checkmate
Internal medicine
Medicine
Oncology
Nivolumab
Enzalutamide
Cohort
Rucaparib
castration resistant
Prostate cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations